Sintetica S.a.

Altergon Sa

Ibsa Institut Biochimique Sa

Altergon Spa

Elisabetta Donati

Augusto Mitidieri

Nicola Caronzolo

Irina Rapaport

Clara Bianchi

Paolo Lualdi

Barbara Piccagli

In a first aspect, the present invention relates to a process for producing a stable, injectable solution with low content of noradrenaline, which includes dissolving noradrenaline and optionally an excipient in deoxygenated or degassed water, filtrating the resulting noradrenaline solution in a nitrogen current, distributing the solution in a nitrogen current, and sterilization, preferably hot. The invention further provides a stable, injectable solution with low content of noradrenaline, substantially free of anti-oxidizing and preservative agents, as well as uses thereof in the medical and pharmaceutical fields.

Process for producing a stable low concentration, injectable solution of noradrenaline

Methods of treatment, pharmaceutically acceptable solutions, and implantable devices are provided for the intrathecal treatment of AED-resistant seizures using levetiracetam.

Intrathecal administration of levetiracetam

The present invention relates to an acetaminophen injectable aqueous solution for use in the treatment or in the prevention of pain by spinal administration, wherein said acetaminophen injectable solution is supersaturated. In certain embodiments, the acetaminophen injectable aqueous solution is administered simultaneously, separately or sequentially with a local anaesthetic by spinal administration.

Injectable supersaturated acetaminophen solution for spinal administration

Topical dosages and formulations of chloroprocaine and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly during ophthalmic procedures or in response to ophthalmic abrasions or trauma.

Topical formulations of chloroprocaine and methods of using same

This invention relates to an injectable pharmaceutical composition based on chloroprocaine or salts and/or derivatives thereof for use in central loco-regional anesthesia by intrathecal administration in repeated doses. Unexpectedly, the intrathecal administration in repeated doses of chloroprocaine does not increase the neurotoxicity of this drug in statistically significant manner.

Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration

The present invention concerns a new use for a composition containing chloroprocaine HCl, and in particular its use for the manufacture of a drug for intrathecal narcosis. The present invention also concerns a new composition containing chloroprocaine HCl, being particularly suited to this new use, as well as a new method for manufacturing the composition.

Use for a composition comprising chloroprocaine HCL, a new composition comprising chloroprocaine HCL and a method for its manufacture

The present invention concerns new preservative-free hyperbaric compositions of prilocaine HCI intended for use in intrathecal narcosis, characterized by high stability at ambient temperature (15&#xb0; C. -27&#xb0; C.). The present invention also concerns a method for manufacturing said compositions.

Stable hyperbaric composition comprising prilocaine HCl, use of said new composition for intrathecal anaethesia, and method for manufacturing said composition

Plaster for topical use having an analgesic activity and at the same time being able to re-absorb haematomas, comprising:

Plaster for topical use containing heparin and diclofenac

Betamethasone- and hyaluronic acid-treated thin adhesive plaster for the treatment of psoriasis dermatitis and dermatosis

A new process, particularly simple and economical, for FSH and LH separation and purification starting from crude HMG preferably urinary, comprising the following steps:

FSH and LH separation and purification process

The salts, in the crystalline form, of ibuprofen and naproxen with N-(2-hydroxyethyl) pyrrolidine are prepared by dissolving ibuprofen and naproxen respectively in a suitable organic solvent, by adding N-(2-hydroxyethyl) pyrrolidine, by letting the compounds react, by removing the solvent and by crystallizing the obtained salt from a solution in an apolar and aprotic solvent. Said salts have a high solubility in water and are used for preparing pharmaceutic compositions for oral and other administrations.

Growing community of inventors

Cavallasca, Italy

Elisabetta Donati